Hi, I'm Shibil — a researcher turned investor based in Chennai. I work at Speciale Invest, a pre-seed/seed deeptech VC firm in India, where I lead deals across biotech, space, defense, and semiconductors.
I write about biology, AI, and deeptech investing at Atoms & Cells — a newsletter at the intersection of where biology and physics become companies. Earlier essays live on Medium.
I've published investment theses on synthetic biology, deeptech in India, and Deeptech 2.0, alongside The Deeptech Fundraising Guide. My book, Deeptech in First Principles, brings together what I've learned about turning technical possibility into dependable companies. I put what I learn into public writing each year as a way of giving back to the ecosystem I learn from. You'll find the essays in the writing archive.
I also build things — AI deal sourcing, autonomous reporting, workout trackers. The best way to evaluate builders is to be one. Everything's on GitHub.
Outside of work: I train seriously — gym, boxing, yoga, swimming, in pursuit of a triathlon. I read across history, philosophy, and science fiction. I write poems occasionally. There's a bookshelf of things I'd recommend.
To see what I'm doing right now, check the now page. For more about me — the full arc from biophysics thesis to femtech startup to Singapore biotech to VC — read the about page. Or just say hi.
Biology and physics becoming companies. Long-form on biotech, AI, and deeptech. No filler.
I’m Shibil. I work at Speciale Invest, backing companies built around difficult problems in science and technology. My work spans biotech, space, defense and semiconductors.
I came to investing through research, a startup that didn’t work out, and biotech operations. That path still shapes the questions I ask: does the science work, what will it take to make it useful, and what kind of company can deliver it?

I grew up in a small town in Kerala, in a joint family. My grandfather was a teacher, entrepreneur and social worker. He was my everything. Much of how I learned to look at the world came through him: stay curious, take people seriously, and try to make yourself useful.
That curiosity took me to IISER Kolkata. I studied biological sciences, explored mathematics and computer science, and did my master’s thesis in biophysics, studying the traction forces of cells. Feynman and Sapolsky became companions along the way. Outside the lab, there were arts, dance, and mentoring students through Ek-Pahel.
After IISER, I worked in a biomechanics lab at IISc. I wanted to take what I was learning beyond research, and in late 2020 I started a women’s healthcare company focused on PCOS. We found some early traction, but I couldn’t build the team and financing needed to scale. The company closed in January 2022.
I then joined TeOra, a Singapore-based biotech startup, leading operations in India. I built relationships with research institutes and CROs, hired and mentored people, and managed animal trials. It taught me how much work sits between an interesting scientific idea and getting something done.
Eventually I took a career break. I explored finance, coding and AI, read widely, and began writing. I didn’t have a neat plan. Those experiments and the conversations they started helped me find my way to Speciale.
Each year I try to put what I’ve learned into something other people can use. That has become investment theses and a fundraising guide, essays, and now Deeptech in First Principles.
I write about biology, AI and deeptech investing at Atoms & Cells. Earlier writing lives on Medium. Publishing is a way to clarify my own thinking and give something back to the people and ecosystem I learn from.
I read across history, fiction, philosophy and science. I write poems, make room for art, and keep returning to new things to learn. My bookshelf is a good place to find some of those influences.
Training is part of my routine: swimming, cycling, running, yoga, boxing and weightlifting. I’m working towards a triathlon. I get bored easily; learning a different discipline tends to bring me back.
I’m proud of the things I tried that didn’t work. They changed what I learned and where I went next.
If you’re building in deeptech, have a question about something I’ve written, or want to talk about science, poetry or philosophy, I’d like to hear from you.
Biology as information, the compression of platform advantages, and the architectures that can keep learning.
Read essay · 19 min →A fifty-year history of biotech platforms, from closed capabilities to open tools and changing sources of value.
Read essay · 30 min →What a discovery system must learn from each experiment for its next experiment to become more valuable.
Read essay · 17 min →How the commoditization of therapeutic modalities changes the opportunity for Indian companies and investors.
Read essay · 36 min →Dilution, ownership, power laws, pharma acquisition economics, and the arithmetic behind biotech venture returns.
Read essay · 42 min →The economics of creating biotech companies: the formation funnel, ownership, capital intensity, and the power law.
Read essay · 19 min →India’s CAR-T manufacturing advantage and the different obstacles facing cell therapy and gene therapy.
Read essay · 13 min →Antibody-drug conjugates, China’s dealmaking advantage, and the affordability opportunity for India.
Read essay · 11 min →India’s semaglutide opportunity, peptide manufacturing, and the limits of a patent-expiry window.
Read essay · 11 min →Bispecific antibodies and what changes when China moves from following a modality to setting its frontier.
Read essay · 12 min →AAV, lipid nanoparticles, and why getting a therapeutic to the right tissue can matter more than its payload.
Read essay · 14 min →The mismatch between AI-native biotech’s changing sources of value and the intellectual-property systems protecting them.
Read essay · 11 min →Synthetic biology through manufacturing economics: cost curves, molecule selection, and the foundry trap.
Read essay · 14 min →Precision fermentation, the cost curve to parity, and India’s potential role in industrial scale-up.
Read essay · 16 min →Where fermentation and cell-free production fit along the spectrum of making molecules with biology.
Read essay · 20 min →The plants, infrastructure, and capital required to turn India’s biological capabilities into manufacturing scale.
Read essay · 15 min →Why a boom in Chinese drug licensing can coexist with a weaker pipeline of new company formation.
Read essay · 19 min →Limited liability, personal guarantees, and how an ecosystem’s treatment of failure shapes its capacity to build.
Read essay · 28 min →Which competitive advantages survive a state-backed push to commoditize an industry, and which disappear.
Read essay · 21 min →China’s solar cost collapse as an industrial opportunity for India—and why importing cheap panels is only a beginning.
Read essay · 10 min →A comprehensive look at where the biotech industry stands — the modality explosion, M&A dynamics, the gap between science and commercialization, and what India's ecosystem needs.
Read on Medium →Synthetic biology is moving from proof-of-concept to product. Which applications are commercially viable first, and what it takes to build a real business on programmable biology.
Read on Speciale →Platform biotech companies promise multiple shots on goal from a single technical capability. Here's how to think about BD strategy, pipeline prioritization, and partnership models.
Read on Speciale →Automation, AI, and programmable biology are collapsing R&D cycles from years to weeks. The next big wave of innovation looks alive.
Read on Medium →A contrarian look at cultured meat economics and biology. Despite hundreds of millions in investment, it's nowhere near cost parity — and may never get there.
Read on Medium →DeepMind's AlphaMissense can predict pathogenicity across 70 million possible missense mutations. What this means for biotech startups and the frontier of synthetic biology.
Read on Medium →Deeptech has outperformed traditional VC by 60–70% over two decades. Two frameworks for timing your entry: AIP and RTPS.
Read the full thesis →An insider's look at what founders should actually ask before signing a term sheet — beyond brand names and check sizes.
Read on Medium →The newsletters, blogs, podcasts, and people that serious venture investors follow across biotech, deeptech, SaaS, and crypto.
Read on Medium →Why synthetic biology and biomimicry represent real sustainability, not green marketing.
Read on Medium →The contrarian case that overcapitalisation causes deeptech startups to stray from the lean, iterative approach the work actually requires.
Read on Medium →Deep tech startups are fundamentally different — built on unproven science with long R&D horizons and different risk profiles.
Read on Medium →A practical guide for deeptech founders raising in India — narrative construction, investor selection, timing, and pitching hard science at pre-seed.
Read the guide →Stories of setbacks and small victories — from a failed startup to an operations role to VC. Every failure was also a door.
Read on Medium →A personal reflection on meaning, suffering, and what gives existence direction — from depression to existentialism to stoicism.
Read on Medium →Lessons on focus, memory, time, sleep, emotion, and learning — built for brains that don't run on default settings.
Read on Medium →I build tools. Some for work, some to scratch an itch, some because the best way to understand a technology is to ship something with it. Most investors evaluate builders from the outside. I'd rather be one.
AI-powered deal sourcing for deeptech VCs. Scans, scores, and surfaces startups worth meeting — built to automate the top of my own funnel.
View source →BYOR — Build Your Own Report. Whitelabel autonomous reporting system. Drop in your data, get structured intelligence out.
View source →Offline-first workout tracker. Upload any workout PDF and track progress. Built because every fitness app wanted a subscription for something a PDF could do.
View source →Personalized diet plans powered by AI. Because nutrition advice shouldn't require a monthly subscription.
View source →Every tool here started as a problem I couldn't find a good solution for. The pattern: encounter friction, build the thing, open-source it. Investing in deeptech founders is better when you've shipped code yourself — you stop romanticizing the product and start respecting the process.
All open source. See everything on GitHub.
Written at different points. Some when I had everything figured out, most when I didn't.
More poems, personal essays, and reflections on life, identity, and what it means to be from where I'm from. Coming when they're ready.
Gym, boxing, yoga, swimming — rotating seriously. In pursuit of a triathlon. The body as a system to optimize, not a background process.
The intersection of biology and AI — where the real leverage points are, and what it would take to build something durable at that boundary.
Open to conversations on deeptech, biotech investing, or anything at the intersection of biology and capital. Also happy to talk history, poetry, and philosophy.
Reach me at [email protected] or on Twitter.